Large-scale market evidence now points one way: focused companies tend to outperform diversified conglomerates, and the payoff from slimming a portfolio unfolds over several years, not overnight. A Boston Consulting Group study of 740 companies in the S&P Global 1200 found that focused firms delivered higher relative total shareholder returns than similarly positioned diversified peers, and that companies completing a "focus transformation" saw their average Tobin's Q ratio improve from 1.5x to 1.7x. Johnson & Johnson's dismantling of its century-old diversified model—separating consumer health as Kenvue and moving to concentrate on Innovative Medicine and MedTech—is the highest-profile test of that logic in healthcare. This article explains why markets reward focus, how J&J's shift illustrates the rationale, and how leaders can evaluate their own portfolios.

The Strategic Imperative: Why Focus Outperforms Diversification

Diversification once defined the modern corporation. For more than a century, J&J built its competitive position across pharmaceuticals, medical devices, and consumer health, with distinct revenue streams, shared financial resources, and resilience across market cycles—as Thani Jambulingam notes in Pharmaceutical Executive, that structure helped establish one of the most enduring corporations in healthcare. The logic was stability: weakness in one business could be offset by strength in another.

The case for focus rests on the mirror image of that argument. Concentrated portfolios let leadership direct capital, talent, and management attention toward fewer, higher-potential businesses, and let investors value each business on its own terms rather than through a conglomerate lens. Markets consistently reward strategic clarity and concentrated resource allocation, BCG's researchers conclude from their data. The result is a widening gap in how the two models are priced and how they perform.